Quick Answer
ASPEN AEROGELS INC reported Total Revenue of $271.10 million for fiscal year 2025.
ASPEN AEROGELS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $271.10M -40.1% |
$452.70M +89.6% |
$238.72M +32.4% |
$180.36M +48.3% |
$121.62M +21.3% |
$100.27M -28.1% |
| Revenue (ASC 606) | $271.10M -40.1% |
$452.70M +89.6% |
$238.72M +32.4% |
$180.36M +48.3% |
$121.62M +21.3% |
$100.27M -28.1% |
| Net Income | -$389.55M -3012.5% |
$13.38M +129.2% |
-$45.81M +44.6% |
-$82.74M -123.0% |
-$37.09M -70.1% |
-$21.81M -49.7% |
| Diluted EPS | -$4.73 -2882.4% |
$0.17 +125.8% |
-$0.66 +68.6% |
-$2.10 -72.1% |
-$1.22 -47.0% |
-$0.83 |
| Total Assets | $406.68M -54.6% |
$895.14M +27.3% |
$703.05M +9.3% |
$643.42M +251.7% |
$182.95M +87.8% |
$97.42M -5.9% |
| Cash and Equivalents | $156.86M -29.0% |
$220.88M +58.1% |
$139.72M -50.3% |
$281.33M +267.5% |
$76.56M +364.1% |
$16.50M +354.1% |
| Long-Term Debt | $65.45M -31.1% |
$94.96M | — | — | — | $2.06M |
| Stockholders Equity | $235.52M -61.7% |
$614.71M +25.9% |
$488.06M +9.1% |
$447.44M +248.4% |
$128.41M +89.2% |
$67.85M +15.0% |
| R&D Expense | $13.42M -25.7% |
$18.05M +10.4% |
$16.36M -3.4% |
$16.93M +48.0% |
$11.44M +31.1% |
$8.73M +3.8% |
| Operating Income | -$378.23M -793.6% |
$54.53M +210.8% |
-$49.20M +37.9% |
-$79.25M -95.2% |
-$40.60M -88.2% |
-$21.57M -52.3% |
| Gross Profit | $46.00M -74.9% |
$182.90M +221.3% |
$56.92M +1043.9% |
$4.98M -49.9% |
$9.94M -31.9% |
$14.59M -44.5% |
| Shares Outstanding | 82.71M +0.8% |
82.04M +7.2% |
76.50M +9.3% |
69.99M +110.7% |
33.22M +19.4% |
27.82M +14.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $73.02M | -37.8% | -6.4% |
| Revenue (ASC 606) | September 30, 2025 | $73.02M | -37.8% | -6.4% |
| Net Income | September 30, 2025 | -$6.33M | +51.2% | +30.1% |
| Diluted EPS | September 30, 2025 | -$0.08 | +52.9% | +27.3% |
| Total Assets | September 30, 2025 | $491.39M | -37.2% | -6.4% |
| Cash and Equivalents | September 30, 2025 | $150.72M | +32.8% | -10.1% |
| Long-Term Debt | September 30, 2025 | $70.09M | -25.2% | -9.3% |
| Stockholders Equity | September 30, 2025 | $305.73M | -39.8% | -1.0% |
| R&D Expense | September 30, 2025 | $2.49M | -45.7% | -34.3% |
| Operating Income | September 30, 2025 | -$3.35M | -119.2% | +35.1% |
| Gross Profit | September 30, 2025 | $20.80M | -57.6% | -17.8% |
| Shares Outstanding | September 30, 2025 | 82.56M | +7.0% | +0.4% |
- ASPEN AEROGELS INC reported Total Revenue of $271.10 million for fiscal year 2025.
- ASPEN AEROGELS INC showed a decrease of -40.1% in Total Revenue compared to the prior fiscal year.
- ASPEN AEROGELS INC reported Revenue (ASC 606) of $271.10 million for fiscal year 2025.
- ASPEN AEROGELS INC showed a decrease of -40.1% in Revenue (ASC 606) compared to the prior fiscal year.
- ASPEN AEROGELS INC reported Net Income of -$389.55 million for fiscal year 2025.
- ASPEN AEROGELS INC showed a decrease of -3012.5% in Net Income compared to the prior fiscal year.
- ASPEN AEROGELS INC reported Diluted EPS of $4.73 per share (loss) for fiscal year 2025.
- ASPEN AEROGELS INC showed a decrease of -2882.4% in Diluted EPS compared to the prior fiscal year.
- ASPEN AEROGELS INC reported Total Assets of $406.68 million for fiscal year 2025.
- ASPEN AEROGELS INC showed a decrease of -54.6% in Total Assets compared to the prior fiscal year.
- ASPEN AEROGELS INC reported Cash and Equivalents of $156.86 million for fiscal year 2025.
- ASPEN AEROGELS INC showed a decrease of -29.0% in Cash and Equivalents compared to the prior fiscal year.
- ASPEN AEROGELS INC reported Long-Term Debt of $65.45 million for fiscal year 2025.
- ASPEN AEROGELS INC showed a decrease of -31.1% in Long-Term Debt compared to the prior fiscal year.
- ASPEN AEROGELS INC reported Stockholders Equity of $235.52 million for fiscal year 2025.
- ASPEN AEROGELS INC showed a decrease of -61.7% in Stockholders Equity compared to the prior fiscal year.
- ASPEN AEROGELS INC reported R&D Expense of $13.42 million for fiscal year 2025.
- ASPEN AEROGELS INC showed a decrease of -25.7% in R&D Expense compared to the prior fiscal year.
- ASPEN AEROGELS INC reported Operating Income of -$378.23 million for fiscal year 2025.
- ASPEN AEROGELS INC showed a decrease of -793.6% in Operating Income compared to the prior fiscal year.
- ASPEN AEROGELS INC reported Gross Profit of $46.00 million for fiscal year 2025.
- ASPEN AEROGELS INC showed a decrease of -74.9% in Gross Profit compared to the prior fiscal year.
- ASPEN AEROGELS INC reported Shares Outstanding of 82.71 million shares for fiscal year 2025.
- ASPEN AEROGELS INC showed an increase of +0.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: